Mouse Model News and Research

RSS

Cancer prevention

Tapping into a growing body of knowledge about the origins and progression of cancer, researchers are now developing and testing new preventive therapies to stop it in its tracks.

15 Apr 2008

Restricted-calorie diets limit development of epithelial cancers

A restricted-calorie diet inhibited the development of precancerous growths in a two-step model of skin cancer, reducing the activation of two signaling pathways known to contribute to cancer growth and development, researchers at The University of Texas M. D. Anderson Cancer Center report today at the American Association for Cancer Research annual meeting.

15 Apr 2008

Exercise leads to significantly greater tumor growth in mouse model

Prostate tumors grew more quickly in mice who exercised than in those who did not, leading to speculation that exercise may increase blood flow to tumors, according to a new study by researchers in the Duke Comprehensive Cancer Center (DCCC) and the Duke Prostate Center.

13 Apr 2008

Biomarkers allow doctors to match therapy to patient

Genetic variations ensure that no two people are exactly alike, nor are their cancers.

13 Apr 2008

Researchers close in on origins of main ingredient of Alzheimer's plaques

The ability of brain cells to take in substances from their surface is essential to the production of a key ingredient in Alzheimer's brain plaques, neuroscientists at Washington University School of Medicine in St. Louis have learned.

10 Apr 2008

Diabetes drug may hold potential as treatment for epilepsy, using same mechanism as ketogenic diet

Two years ago, University of Wisconsin-Madison scientists reported they had suppressed epileptic seizures in rats by giving them a glycolytic-inhibitor, inhibiting the brain's ability to turn sugar into excess energy and blocking the expression of seizure-related genes.

9 Apr 2008

Scientists block early step in metastasis of prostate cancer cells

Recent studies have suggested an association between chronic inflammation and cancers of the prostate, colon, stomach and liver.

9 Apr 2008

Potential new therapy for myeloproliferative disorders

A unique partnership between industry and academia has led to human clinical trials of a new drug for a rare class of blood diseases called myeloproliferative disorders (MPD), which are all driven by the same genetic mutation and can evolve into leukemia.

8 Apr 2008

Asthma and smoker's lung: dry airways play a key role

Dry airways may not only play a central role in the development of the inherited lung disease cystic fibrosis, but also in much more common acquired chronic lung diseases such as asthma and smoker's lung, the cigarette smoke-induced chronic obstructive pulmonary disease (COPD).

8 Apr 2008

New mouse model grants insight into the genetic and molecular mechanisms underpinning acute myeloid leukemia

Leukaemia - cancer of blood or bone marrow is caused by mutations that allow defective blood cells to accumulate and displace healthy blood.

8 Apr 2008

Synthetic molecules may be less expensive alternative to therapeutic antibodies

Researchers at UT Southwestern Medical Center have developed a simple and inexpensive method to screen small synthetic molecules and pull out a handful that might treat cancer and other diseases less expensively than current methods.

7 Apr 2008

Rare genetic syndrome may hold key to cure for heat stroke

A genetic disorder that can cause a fatal rise in body temperature in some patients undergoing general anesthesia may hold the key to a cure for heat stroke, according to research published in the April 4 edition of the journal Cell.

4 Apr 2008

Potential new treatments for polycystic kidney disease

A family of small molecules called CFTR inhibitors show promising effects in slowing the progression of polycystic kidney disease (PKD), the most common genetic disease of the kidneys, according to preliminary research reported in the July 2008 issue of the Journal of the American Society Nephrology.

3 Apr 2008

Unraveling how a drug helps patients with multiple sclerosis

Although the drug IFN-beta is commonly used to treat individuals with the relapsing-remitting form of multiple sclerosis (MS), little is known about the mechanism(s) by which it acts.

2 Apr 2008

Bosentan drugs offers new approach to limiting organ damage in sickle cell disease

Sickle cell disease (SCD) is so called because of the abnormal sickle shape of the red blood cells in individuals with this blood disorder.

2 Apr 2008

Lyme disease - a tough nut to crack!

The bacteria that cause Lyme disease, the most common tick-borne illness in the United States, can linger in mouse tissues long after a full round of antibiotic treatment is completed, report researchers from the University of California, Davis.

2 Apr 2008

Exercise delays onset of Huntington’s in mouse model

The simple act of running in an exercise wheel delays the onset of some symptoms of Huntington's disease in a mouse model of the fatal human disorder according to research published in the open-access journal BMC Neuroscience.

1 Apr 2008

Potential new target for multiple sclerosis therapy

Researchers demonstrate both genetic and pharmaceutical evidence for the role of a protein called collagenase-2 in the development of multiple sclerosis (MS), providing a potential new way to combat this debilitating disease.

31 Mar 2008

Umbilical cord blood cell therapy may reduce signs and symptoms of Alzheimer's disease

Targeted immune suppression using human umbilical cord blood cells may improve the pathology associated with Alzheimer's disease, a new study in a mouse model of this currently untreatable neurodegenerative condition reports.

28 Mar 2008

Anticancer siRNA therapy advances, thanks to nanoparticles

Small pieces of nucleic acid, known as siRNAs (short interfering RNAs), can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials. Now, three new reports highlight the progress that researchers are making in developing broadly applicable, nanoparticle-enabled siRNA anticancer therapeutics.

28 Mar 2008